Bright Minds Biosciences Inc. announced that the International Searching Authority reviewed its international patent application directed to phenethylamine compounds and issued a Written Opinion indicating that Bright Minds' core phenethylamine compounds of interest are novel and inventive over the searched prior art. Bright Minds recently filed an international patent application (assigned a filing number of PCT/CA2023/050003) directed at compounds that belong to the phenethylamine class of molecules, which the Company believes are potentially best in class compounds with an optimized short half-life, highly potent and extreme selectivity relative to other 5-HT(2A) agonists in development. Compounds from the Company's 5-HT(2A), and 5-HT(2 A) /5-HT(2C) programs are contained in this patent application, including its lead 5-HT (2A) agonist, BMB 202, as well as other backup and compounds of high interest from both programs. While the Written Opinion is non-binding, the Written Opinion is encouraging news and supports the view that Bright Minds has developed patentable phenethylamine compounds.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.43 CAD | 0.00% | -6.54% | -32.55% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.55% | 4.69M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- DRUG Stock
- News Bright Minds Biosciences Inc.
- Bright Minds Biosciences Inc. Receives Favorable Written Opinion from the International Searching Authority for BMB-202